NIH leads adaptive phase II clinical trial for COVID-19 mAb

By The Science Advisory Board staff writers

August 4, 2020 -- The National Institutes of Health (NIH) is now studying an investigational monoclonal antibody (mAb), Ly-CoV555, as part of an adaptive phase II clinical trial.

ACTIV-2, established by NIH's Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) and Operation Warp Speed. The flexible design will allow the study to expand from a phase II to a phase III trial if the investigational treatment Ly-CoV555 shows promise, without delay. The investigational therapy was discovered by Abcellera Biologics in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and subsequently developed and manufactured by Eli Lilly in partnership with Abcellera.

The primary goal of ACTIV-2 is to evaluate safety of the mAb treatment. The study will enroll patient volunteers currently infected with SARS-CoV-2 who have mild to moderate disease but who are not hospitalized. Initially, 220 volunteers will be enrolled and assigned to receive either an intravenous infusion of Ly-CoV555 or placebo infusion.

Investigators will test to see if the SARS-CoV-2 RNA can still be detected 28 days post-treatment. Patients will also receive pulse oximetry tests to determine the therapeutic effect on blood oxygen levels. Blood samples will be taken to understand how the therapy is affecting the course of SARS-CoV-2 infection. Participants will be followed for up to 24 weeks.

If successful, the trial will transition to a phase III study and enroll an additional 1,780 outpatient volunteers.

NIH launches clinical trial for COVID-19 antibody treatment
The National Institutes of Health (NIH) has started enrolling volunteers in a phase III randomized, controlled clinical trial to test multiple monoclonal...
Lilly begins phase III trial of COVID-19 antibody treatment
Eli Lilly has begun a phase III trial of its lead COVID-19 antibody treatment candidate, Ly-CoV555.
Lilly begins phase III trial for COVID-19 therapy
Eli Lilly has enrolled patients in a phase III study to evaluate the efficacy and safety of baricitinib in hospitalized adults with COVID-19.
Lilly begins trial for 2nd COVID-19 antibody therapy
Eli Lilly and its partner Junshi Biosciences of Shanghai, China, have begun a phase I clinical trial for Eli Lilly's second COVID-19 antibody therapy.
Lilly begins COVID-19 antibody treatment clinical trials
Eli Lilly announced that the first patients have been dosed with its lead COVID-19 antibody treatment candidate, LY-CoV555, according to the firm. The...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter